Dr. Kyu-Tae Kim received his BSc and MSc degrees in Biochemistry from Yonsei University, Seoul, Korea, and his PhD in Biochemistry and Molecular Genetics from the University of New South Wales, Sydney, Australia. He was a Postdoctoral Fellow at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Then, Dr. Kim joined as a Lecturer for the Faculty of Health, School of Biomedical Sciences and Pharmacy at University of Newcastle, Australia. Dr Kim is currently a Chief Science Officer and Director of BD&L of AbClon Inc., an innovative therapeutic antibody drug company listed in KOSDAQ, Seoul, Korea. Dr. Kim has published many papers and presented his findings in prestigious scientific meetings including as invited speakers at the CHI’s PepTalk 2014 & 2016, PEGS 2015, 6th Biologics World Korea 2017 (Session Chair and Panel Discussion), Cell Therapy World Asia 2018.